• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

白细胞表面生物标志物提示散发性阿尔茨海默病固有免疫缺陷。

Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease.

机构信息

The Florey Institute of Neuroscience, the University of Melbourne, Parkville, Victoria, Australia.

The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia.

出版信息

Alzheimers Dement. 2023 May;19(5):2084-2094. doi: 10.1002/alz.12813. Epub 2022 Nov 9.

DOI:10.1002/alz.12813
PMID:36349985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10166765/
Abstract

INTRODUCTION

Blood-based diagnostics and prognostics in sporadic Alzheimer's disease (AD) are important for identifying at-risk individuals for therapeutic interventions.

METHODS

In three stages, a total of 34 leukocyte antigens were examined by flow cytometry immunophenotyping. Data were analyzed by logistic regression and receiver operating characteristic (ROC) analyses.

RESULTS

We identified leukocyte markers differentially expressed in the patients with AD. Pathway analysis revealed a complex network involving upregulation of complement inhibition and downregulation of cargo receptor activity and Aβ clearance. A proposed panel including four leukocyte markers - CD11c, CD59, CD91, and CD163 - predicts patients' PET Aβ status with an area under the curve (AUC) of 0.93 (0.88 to 0.97). CD163 was the top performer in preclinical models. These findings have been validated in two independent cohorts.

CONCLUSION

Our finding of changes on peripheral leukocyte surface antigens in AD implicates the deficit in innate immunity. Leukocyte-based biomarkers prove to be both sensitive and practical for AD screening and diagnosis.

摘要

简介

在散发性阿尔茨海默病（AD）中，基于血液的诊断和预后对于识别有治疗干预风险的个体非常重要。

方法

通过流式细胞术免疫表型分析，共检查了 34 种白细胞抗原。通过逻辑回归和接收者操作特征（ROC）分析对数据进行了分析。

结果

我们确定了 AD 患者中差异表达的白细胞标记物。通路分析显示，涉及补体抑制上调和货物受体活性以及 Aβ清除下调的复杂网络。一个包括四个白细胞标记物（CD11c、CD59、CD91 和 CD163）的拟议面板，预测了患者的 PET Aβ状态，曲线下面积（AUC）为 0.93（0.88 至 0.97）。CD163 在临床前模型中表现最佳。这些发现已经在两个独立的队列中得到了验证。

结论

我们在 AD 外周白细胞表面抗原上发现的变化表明先天免疫缺陷。基于白细胞的生物标志物被证明对 AD 的筛查和诊断具有敏感性和实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b4/10955770/9aa16c708782/ALZ-19-2084-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b4/10955770/66c302d68de3/ALZ-19-2084-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b4/10955770/353fb2f45357/ALZ-19-2084-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b4/10955770/bd4fa4ed4368/ALZ-19-2084-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b4/10955770/9aa16c708782/ALZ-19-2084-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b4/10955770/66c302d68de3/ALZ-19-2084-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b4/10955770/353fb2f45357/ALZ-19-2084-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b4/10955770/bd4fa4ed4368/ALZ-19-2084-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b4/10955770/9aa16c708782/ALZ-19-2084-g003.jpg

相似文献

1
Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease.白细胞表面生物标志物提示散发性阿尔茨海默病固有免疫缺陷。
Alzheimers Dement. 2023 May;19(5):2084-2094. doi: 10.1002/alz.12813. Epub 2022 Nov 9.
2
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍（MCI）患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
3
Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease.多分析物蛋白质组学分析鉴定出临床前阿尔茨海默病患者血液中的神经炎症、脑血管和突触生物标志物。
Mol Neurodegener. 2024 Oct 10;19(1):68. doi: 10.1186/s13024-024-00753-5.
4
A Novel Design of a Portable Birdcage via Meander Line Antenna (MLA) to Lower Beta Amyloid (Aβ) in Alzheimer's Disease.一种通过曲折线天线（MLA）设计的便携式鸟笼，用于降低阿尔茨海默病中的β淀粉样蛋白（Aβ）。
IEEE J Transl Eng Health Med. 2025 Apr 10;13:158-173. doi: 10.1109/JTEHM.2025.3559693. eCollection 2025.
5
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.阿尔茨海默病匹配先导研究 - 远程采集用于临床前阿尔茨海默病试验的血浆生物标志物的可行性。
J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi: 10.14283/jpad.2024.101.
6
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.肾功能对阿尔茨海默病血液生物标志物的影响：对预测淀粉样蛋白-β阳性的意义。
Alzheimers Res Ther. 2025 Feb 19;17(1):48. doi: 10.1186/s13195-025-01692-z.
7
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍（MCI）患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
8
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.淀粉样蛋白 PET 和 tau-PET 评估唐氏综合征患者症状性阿尔茨海默病的时间轴：一项纵向队列研究。
Lancet Neurol. 2024 Dec;23(12):1214-1224. doi: 10.1016/S1474-4422(24)00426-5.
9
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
10
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).¹⁸F - 氟代脱氧葡萄糖正电子发射断层显像（¹⁸F - FDG PET）用于轻度认知障碍（MCI）患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2.

引用本文的文献

1
Integrating genetic and immune profiles for personalized immunotherapy in Alzheimer's disease.整合基因和免疫图谱以实现阿尔茨海默病的个性化免疫治疗。
Front Med (Lausanne). 2025 Jun 2;12:1603553. doi: 10.3389/fmed.2025.1603553. eCollection 2025.
2
Neuroinflammation: A Driving Force in the Onset and Progression of Alzheimer's Disease.神经炎症：阿尔茨海默病发病及进展的驱动因素
J Clin Med. 2025 Jan 8;14(2):331. doi: 10.3390/jcm14020331.
3
Clearance and transport of amyloid β by peripheral monocytes correlate with Alzheimer's disease progression.

本文引用的文献

1
Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease.澳大利亚成像、生物标志物与生活方式（AIBL）研究十五年：来自2359名老年人的进展与观察，涵盖从认知正常到阿尔茨海默病的整个范围
J Alzheimers Dis Rep. 2021 Jun 3;5(1):443-468. doi: 10.3233/ADR-210005. eCollection 2021.
2
Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging.大规模血浆蛋白质组学分析鉴定出用于阿尔茨海默病筛查和分期的高性能生物标志物组合。
Alzheimers Dement. 2022 Jan;18(1):88-102. doi: 10.1002/alz.12369. Epub 2021 May 25.
3
外周单核细胞对淀粉样β的清除和转运与阿尔茨海默病的进展相关。
Nat Commun. 2024 Sep 12;15(1):7998. doi: 10.1038/s41467-024-52396-1.
4
Peripheral blood amyloid-β involved in the pathogenesis of Alzheimer's disease via impacting on peripheral innate immune cells.外周血淀粉样-β通过影响外周固有免疫细胞参与阿尔茨海默病的发病机制。
J Neuroinflammation. 2024 Jan 4;21(1):5. doi: 10.1186/s12974-023-03003-5.
Single-cell peripheral immunoprofiling of Alzheimer's and Parkinson's diseases.
单细胞外周免疫分析阿尔茨海默病和帕金森病。
Sci Adv. 2020 Nov 25;6(48). doi: 10.1126/sciadv.abd5575. Print 2020 Nov.
4
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.与临床正常老年人淀粉样蛋白负担增加相关的因素。
JAMA Neurol. 2020 Jun 1;77(6):735-745. doi: 10.1001/jamaneurol.2020.0387.
5
Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease.血浆tau蛋白在阿尔茨海默病的诊断中可补充脑脊液tau蛋白和磷酸化tau蛋白。
Alzheimers Dement (Amst). 2019 Jun 28;11:483-492. doi: 10.1016/j.dadm.2019.05.001. eCollection 2019 Dec.
6
Genetic risk for Alzheimer's disease is concentrated in specific macrophage and microglial transcriptional networks.阿尔茨海默病的遗传风险集中在特定的巨噬细胞和小胶质细胞转录网络中。
Genome Med. 2018 Feb 26;10(1):14. doi: 10.1186/s13073-018-0523-8.
7
High performance plasma amyloid-β biomarkers for Alzheimer's disease.用于阿尔茨海默病的高性能血浆淀粉样蛋白-β生物标志物。
Nature. 2018 Feb 8;554(7691):249-254. doi: 10.1038/nature25456. Epub 2018 Jan 31.
8
A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain.阿尔茨海默病的系统观——超越大脑的淀粉样蛋白-β代谢的新见解。
Nat Rev Neurol. 2017 Sep 29;13(10):612-623. doi: 10.1038/nrneurol.2017.111.
9
The role of complement inhibitors beyond controlling inflammation.补体抑制剂的作用不仅限于控制炎症。
J Intern Med. 2017 Aug;282(2):116-128. doi: 10.1111/joim.12606. Epub 2017 Mar 26.
10
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.A/T/N：阿尔茨海默病生物标志物的无偏描述性分类方案。
Neurology. 2016 Aug 2;87(5):539-47. doi: 10.1212/WNL.0000000000002923. Epub 2016 Jul 1.